Bristol-Myers Squibb (NYSE:BMY), #12 in sales in 2006 and #13 in R&D in 2006 with $2.32 bn EUR budget still hasn’t managed to pull out of the mess of the last few years. While it has a few strategic partnerships with various 
pharmaceuticals, the company recently announced that it would not ask for U.S. Food and Drug approval for vinflunine, a bladder drug. Add in the company handing out an undisclosed number of pink slips and the new black box warning on Definity and things aren’t looking optimistic for BMS
Phase III Drugs:
Ixabepilone - Breast cancer, Metastic breast cancer
Vinflunine - Gastric cancer, Transitional Cell Carcinoma of the Urothelial Tract, Bladder Cancer, Bladder Neoplasms, Transitional Cell Carcinoma, Metastasis
Ipilimumab - Melanoma
Belatacept - Renal Transplant, Kidney Transplantation, Chronic Kidney Failure
Saxagliptin - Type 2 Diabetes Mellitus, Type 2 Diabetes
Apixaban - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Atrial Flutter, Venous Thrombosis, Pulmonary Embolism
[Source: FierceBiotech]
.jpg)
» 2007 Edition of the European Commission's Report of R&D Spending from PharmaGazette
The 2007 edition of the European Commission's annual report of research and development spending places Pfizer Inc. at the top of the heap outspending all other industries.Pharmaceuticals and biotechnology became the top R&D spenders beating ou... [Read More]
Tracked on: December 14, 2007 2:18 PM | Permalink to Trackback